A future diabetes pandemic

1
A future diabetes pandemic taking action now
Lise Kingo Executive Vice President Novo
Nordisk A/S
2
(No Transcript)
3
...You are sharing this small planet with well
over a billion people who are denied the very
minimum requirements of human dignity, and with 4
or 5 billion whose choices in life are narrow
indeed compared to yours.
Kofi Annan
4
Diabetes a future pandemic disease
5
Diabetes a future pandemic
350
Year 2030 370 mio.
300
250
200
150
100
50
0
2030
1995
2000
2005
2010
2015
2020
2025
6
Diabetes per 1000 inhabitants
100
1995
2000
80
2025
60
40
20
0
Africa
Europe
SE Asia
Americas
In WHO Report 1997 Conquering Suffering,
Enriching Humanity
7
(No Transcript)
8
The sufferings from diabetes

• Life expectancy is reduced by 5 to 10 years
• Earlier death due to myocardial disease is
• increased two to five fold
• Stroke is increased two-fold
• Renal failure 40 of all dialysed patients
• have diabetes
• New blindness 30 of all cases are people
• with diabetes
• gt90 of these have type 2 diabetes
• Two out of three amputees have diabetes

9
The costs of diabetes
With the present trend Diabetes and its
Complications, will take more than one third of
the health budgets in only 15 to 20 years if
vigorous steps to slow the Progress of this
epidemic are not taken Source Orahilly,
Science, medicine and the future.
Non-insulin-dependent diabetes mellitus the
gathering storm. BMJ vol 314 March 1997
10
Learnings from the AIDS/HIV epidemic
11
AIDS, breast cancer and diabetes in the US
Diabetes affects more people, kills more people
and costs more than AIDS and breast cancer
together
No afflicted
Annual deaths
Costs
AIDS and breast cancer
3.4 Million
94,000
USD 16.9 Billion
Diabetes
16 Million
160,000
USD 91.1 Billion
Source US Government Data 2000
12
Access to health in developing countries WHO
recommendations

• Development of national health strategies
• Building of national healthcare capacity
• Best possible pricing
• Additional funding

13
(No Transcript)
14
What would this mean for diabetes?
15
National priority
16
National Diabetes Strategies

• Novo Nordisk facilitates collaboration on
  implementation of national strategies for
  diabetes prevention and treatment
• We aim at identifying best practices from around
  the world and help national governments in
  implementing them
• The programme is systematic and can be a template
  for the other chronic diseases (CVD,
  hypertension)

17
(No Transcript)
18
Understanding patients needs
19
DAWN
Diabetes Attitudes, Wishes and Needs

• 30 of patients report a feeling of poor
  well-being
• 10 of patients report a feeling of good
  well-being
• More than 30 of nurses feel that patients have
  difficulties communicating with their doctors
• Less than 50 of health care providers feel able
  to identify and evaluate their patients
  psychological needs

20
(No Transcript)
21
Pricing
22
Pricing Policy in LDC Countries

• Novo Nordisk offers its insulin products to the
  public health systems in the poorest countries at
  prices not to exceed 20 of the average price in
  North America, Europe and Japan

LDC as defined by UN 49 countries in Africa,
Asia-Pacific and Central America
23
(No Transcript)
24
Additional funding
25
The World Diabetes Foundation

• The main purpose of the WDF is
• To support projects that aim at improving
  diabetes treatment in developing countries
• Novo Nordisk will donate approx. 67 mio EUR to
  the WDF over the next 10 years
• WDF is an independent foundation with a Board
  consisting of leading specialists in the field of
  diabetes, NGO- and Novo Nordisk representatives

26
(No Transcript)
27
Business model required
28
OPENNESS
29
DIALOGUE
30
DECENCY
31
Governments only find the courage and resources
to do the right thing when business takes the
lead.
Kofi Annan
32
A broad business perspective
VISION
Core Values(Accountable, ambitious, responsible,
engaged with stakeholders, open honest, ready
for change)
Commitments (Economic, environmental and social
responsibility)
Methodology
Triple Bottom Line reporting
Facilitations
Balanced Business Scorecard
33
The Triple Bottom Line
Economically viable

• Financial
• Socio- health economics

Environmentally sound
Socially responsible

• Employees
• Patients
• Communities

• Environment
• Animals
• Bioethics

34
Novo Nordisk financial performance
2000
2001
2002
Net turnover
20,811
23,776
25,187
Operating profit margin
23,1
23,6
23,7
No of employees
18,005
16,141
13,752
35
It can be done Novo Nordisk Vision
36
The hottest places in Hell are reserved for
those who, in time of great moral crisis,
maintain their neutrality
Dante